R&M's Sergeant: 'There are a huge number of anomalies for value managers to exploit this year'

Value at ‘multi-generational low’

James Baxter-Derrington
clock • 1 min read

Value stocks are at a “multi-generational low” and 2022 presents a “huge number of anomalies for value managers to exploit”, according to head of value and recovery at River and Mercantile, Hugh Sergeant.

Despite 2021 being "another frustrating year for value managers", Sergeant believes it also set up "one of the greatest relative investment opportunities" of his almost three-decade career. 'Too much debt in system' is likely to make recent value/growth rotation transitory "2021 should have been a value and recovery year," he said. "But the market still had many things to worry about (such as the spread of new Covid variants) and bond markets decided that real yields should be as negative as possible, despite strong economic growth and reflation. "Last year therefore became another...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot